Cytokinetics, Inc. Share Price Nasdaq
Equities
US23282W1009
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
15/05 | Transcript : Cytokinetics, Incorporated - Shareholder/Analyst Call | |
13/05 | Transcript : Cytokinetics, Incorporated - Special Call |
Sales 2024 * | 97.01L 81Cr | Sales 2025 * | 7.52Cr 626.51Cr | Capitalization | 628.28Cr 52TCr |
---|---|---|---|---|---|
Net income 2024 * | -49Cr -4.08TCr | Net income 2025 * | -47Cr -3.88TCr | EV / Sales 2024 * | 644 x |
Net cash position 2024 * | 3.39Cr 282.42Cr | Net cash position 2025 * | 42Cr 3.47TCr | EV / Sales 2025 * | 78 x |
P/E ratio 2024 * |
-12.6
x | P/E ratio 2025 * |
-14.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.45% |
Latest transcript on Cytokinetics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Robert Blum
CEO | Chief Executive Officer | 60 | 01/98/01 |
Kari Loeser
CMP | Compliance Officer | - | 01/21/01 |
Stuart Kupfer
CTO | Chief Tech/Sci/R&D Officer | - | 01/20/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nancy Wysenski
BRD | Director/Board Member | 66 | 20/20/20 |
Edward Kaye
BRD | Director/Board Member | 75 | 20/16/20 |
Santo Costa
BRD | Director/Board Member | 78 | 01/10/01 |
1st Jan change | Capi. | |
---|---|---|
+9.42% | 11TCr | |
+11.84% | 10TCr | |
-14.15% | 2.24TCr | |
-1.05% | 2.23TCr | |
-5.29% | 1.91TCr | |
-38.29% | 1.8TCr | |
-4.16% | 1.79TCr | |
+7.99% | 1.43TCr | |
+36.24% | 1.25TCr |